A head-to-head randomised controlled trial of aripiprazole versus quetiapine as augmenting agents in treatment-resistant depression
-
Published:2022
Issue:3
Volume:12
Page:307
-
ISSN:2321-8568
-
Container-title:Advances in Human Biology
-
language:en
-
Short-container-title:Adv Hum Biol
Subject
Ocean Engineering
Reference18 articles.
1. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder;Bauer;J Affect Disord,2010
2. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomised, double-blind, placebo-controlled study;Marcus;J Clin Psychopharmacol,2008
3. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II);McElroy;J Clin Psychiatry,2010
4. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care;Bauer;World J Biol Psychiatry,2007
5. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomised, double-blind, placebo-controlled study;Berman;J Clin Psychiatry,2007